Tiago Girão Biography and Net Worth

CFO of Immunovant

Tiago is a seasoned executive with over 20 years of experience leading finance, accounting, and operations for both public and private companies. Prior to joining Immunovant, Tiago served as the Chief Financial Officer for several Roivant subsidiaries. He was previously the Chief Financial Officer of Cytori Therapeutics, Inc. from 2014 to 2019 and held senior leadership roles at NuVasive, Inc. Tiago began his career in the audit practices of Ernst & Young and KPMG, where he gained over a decade of foundational experience. He also served on the Board of Directors of Landos Biopharma, Inc. from 2021 until its acquisition by AbbVie Inc. in early 2024.

Tiago holds an accounting degree from the Universidade de Fortaleza in Brazil and is a licensed CPA in the state of California.

What is Tiago Girão's net worth?: The estimated net worth of Tiago Girão is at least $7.08 million as of April 23rd, 2026. Mr. Girão owns 247,596 shares of Immunovant stock worth more than $7,076,294 as of April 27th. This net worth evaluation does not reflect any other investments that Mr. Girão may own. Learn More about Tiago Girão's net worth.
How do I contact Tiago Girão?: The corporate mailing address for Mr. Girão and other Immunovant executives is 320 WEST 37TH STREET, NEW YORK NY, 10018. Immunovant can also be reached via phone at 917-580-3099 and via email at [email protected]. Learn More on Tiago Girão's contact information.
Has Tiago Girão been buying or selling shares of Immunovant?: In the last ninety days, Tiago Girão has sold $763,011.20 of Immunovant stock. Most recently, Tiago Girao sold 25,760 shares of the business's stock in a transaction on Thursday, April 23rd. The shares were sold at an average price of $29.62, for a transaction totalling $763,011.20. Following the completion of the sale, the chief financial officer now directly owns 247,596 shares of the company's stock, valued at $7,333,793.52. Learn More on Tiago Girão's trading history.
Who are Immunovant's active insiders?: Immunovant's insider roster includes Peter . (), Eva Barnett (CFO), Julia Butchko (Insider), Andrew Fromkin (Director), Michael Geffner (Chief Medical Officer), Tiago Girão (CFO), Melanie Gloria (COO), Douglas Hughes (Director), Mark Levine (Chief Legal Officer and Corporate Secretary), William Macias (Insider), George Migausky (Director), Atul Pande (Director), Peter Salzmann (CEO), Jay Stout (CTO), Frank Torti (Director), and Christopher Van Tuyl (Chief Legal Officer and Corporate Secretary). Learn More on Immunovant's active insiders.
Are insiders buying or selling shares of Immunovant?: During the last twelve months, Immunovant insiders bought shares 1 times. They purchased a total of 16,666,666 shares worth more than $349,999,986.00. During the last twelve months, insiders at the sold shares 21 times. They sold a total of 149,348 shares worth more than $3,678,496.15. The most recent insider tranaction occured on April, 23rd when CFO Tiago Girao sold 25,760 shares worth more than $763,011.20. Insiders at Immunovant own 1.8% of the company. Learn More about insider trades at Immunovant.
Information on this page was last updated on 4/23/2026.

Tiago Girão Insider Trading History at Immunovant

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
4/23/2026	Sell	25,760	$29.62	$763,011.20	247,596

Tiago Girão Buying and Selling Activity at Immunovant

Immunovant Company Overview

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Today's Range

Now: $29.10

$28.47

$29.21

50 Day Range

MA: $25.99

$22.98

$29.49

2 Week Range

Now: $29.10

$13.36

$30.09

Volume

48,069 shs

Average Volume

1,421,313 shs

Market Capitalization

$5.92 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.67